Hospitals Buy the Drug Cheap and Bill It at Full Price

A Discount With No Matching Obligation

Start with the simple mechanics because the structure here is strange enough that it needs to be expressed directly before anything else is placed on top of it.under the federal government 340B drug pricing program pharmaceutical manufacturers must sell covered outpatient drugs to eligible hospitals and clinics at a large legal discount. Those hospitals then bill insurers and patients at regular rates. No one adjusts the bill downward to match what the hospital actually paid. The difference is on the hospital

This is the part that caught me by surprise when I first read the statute carefully. That discount does not have to go to the patient who received the drug. There is no requirement that the retained differential fund any particular activity. Congress drafted language expressing the intent that covered entities use the savings to leverage scarce resources to reach more patients. That intent was never made into an enforceable spending rule a reporting requirement or an audit trail. It reads like a clause.of purpose next to a blank check

Why Manufacturers Participate Anyway

No one chooses this deal in any meaningful sense. A drug manufacturer that refuses to sell at $340 billion prices loses Medicaid and Medicare Part B coverage for that drug and for most products which is almost commercially fatal since those two programs affect a large proportion of the prescriptions written in the country. So the discount is not really a negotiated concession. It is the toll a manufacturer pays for shelf space in the two largest government drug programs

The size of the discount comes from a formula tied to Medicaid reimbursement mechanics and for some drugs especially higher-priced ones it is large. Combine a high acquisition price of $340 billion with billing at full commercial rates and the per-unit margin can exceed anything else on a hospital's books. A single cancer drug administered a few hundred times a year can generate a larger retention margin than an entire line of inpatient services

A Worked Example: Pricing the Spread on One Drug

Numbers make this concrete faster than another paragraph of description so let me build one from scratch. Each figure here is illustrative not the actual price of a real drug but the arithmetic works exactly as it would for a real product

Let's say that a hospital's oncology infusion center administers an infused biological product whose non-340B acquisition cost that is what a hospital without the designation would pay through an ordinary group purchasing contract is around $3,000 per dose. Let's assume that the $340 billion discount on this particular drug is equivalent to a 40 percent discount on that price. This puts the hospital's actual acquisition cost at $3,000.dollars multiplied by 0.60 that is $1,800 per dose

Now suppose that the hospital bills a commercial insurer a negotiated outpatient infusion rate of $4,500 for that same dose a figure well within the range that hospitals actually negotiate for specialty infusion. The spread on a single dose is 4,500 minus 1,800 or $2,700. That is the margin captured in one administration and has nothing to do with the cost of nursing time the infusion chair or anything else thathas actually been invested in administering the medication that day

Expand. Suppose this infusion center treats 20 patients a month with this drug and each receives a monthly dose which is equivalent to 240 doses in a year. Multiply 240 by the spread of $2,700 and the center generates $648,000 a year in retained margin on this drug alone. That's not counting the 340 billion eligible drugs dispensed by the same hospital and a large system ofSafety net can have hundreds running in its outpatient pharmacies and infusion centers at a time. This is exactly why hospital finance departments follow the 340 billion margin as its own line instead of allowing it to blend with the broader figures

How a Modest Program Became a Large One

Two expansions account for almost all of the growth. The first was eligibility. Over time Congress and regulators expanded the categories of qualified entities to include critical access hospitals rural referral centers and various other classes of providers. Each expansion added participants and the program's footprint grew accordingly

In my opinion the second expansion was more important. Covered entities were granted permission to dispense 340B drugs through third-party retail pharmacies operating under contract rather than solely through their own in-house pharmacy. I believe this is the most significant design change in the history of the program. It severed the link between the hospital serving a low-income population and the physical site that actually dispenses the patient's prescription. A qualifying hospital could now capture a $340 billion margin on a prescription filled in onepharmacy chain many miles from anyone you actually treat

Put those two changes together and the program's purchases grew from a modest initial figure to tens of billions of dollars a year making 340B one of the nation's largest drug pricing agreements by volume

The Counterargument: The Hospital Case, Taken Seriously

It would be easy to write this article as a story about a loophole and I want to resist that temptation because the hospital argument is not a topic of conversation. It might be the strongest defense in health care financing for keeping a policy exactly this strange on the books

Safety-net hospitals treat huge numbers of uninsured and underinsured patients and federal law requires their emergency departments to stabilize anyone who comes in regardless of their ability to pay. That care is not optional and is far from being fully reimbursed. Medicaid payment rates in most states are below the actual cost of providing the care and self-pay patients often pay little or nothing. Someone has to fill that gap and for decades in American health care that someoneIt has effectively been the hospital itself

The $340 billion margin is one of the few funding sources created specifically to plug that hole. Hospitals use it to subsidize charity care community health clinics behavioral health programs and outreach work that no payer funds directly because none of those activities generate a bill of their own. A rural hospital operating on a slim operating margin can have its entire behavioral health program paid for by distributing a handful of high-cost infused drugs

If the subsidy is eliminated nothing currently on the table will replace it. No legislature has passed a direct appropriation large enough to fill the gap and there is no alternative reimbursement mechanism in reserve. Hospitals are not wrong when they say that an imperfect subsidy is better than no subsidy. If the real choice is between unmonitored spread and a program that quietly closes a rural behavioral health clinic spread is obviously not the worst option even if it is a strange way to fund something on purpose

The Case From Manufacturers and Other Critics

The other side of this argument is just as blunt and deserves the same respect I just gave the hospital case. The program has grown far beyond its original scale and critics point out that documented charity care has not grown at the same rate. Several studies have found only a weak correlation between the size of a hospital's $340 billion margin and the amount of uncompensated care that hospital actually provides. Some have also found that relationships with contract pharmacies expand into areasprosperous with many insured patients rather than focusing on the underserved communities around which the program was built

There is a second more pointed criticism worth considering. Because the retained margin increases with the drug's list price the program gives a covered entity a financial incentive to prefer the most expensive drug in a class to a cheaper equally effective one. In reality no one has to act on that incentive for it to be worth mentioning out loud. Critics also point out that hospitals' acquisitions of medical offices are motivated in part by 340B eligibility. A clinicthat was previously ineligible may become 340B eligible once a qualified hospital owns it and that change of ownership alone alters what the practice earns on the exact same prescriptions it was already writing the day before

Case Study: Eli Lilly and the Contract Pharmacy Standoff

The clearest real-world example of how this dispute plays out is the contract pharmacy standoff that began in the summer of 2020. Eli Lilly was one of the first manufacturers to announce that it would stop shipping certain $340 billion-priced drugs to hospitals' outside contract pharmacies arguing that statute never required it to ship through an unlimited number of pharmacies chosen by the hospital. Other manufacturers including Sanofi and Novartis adopted similar restrictions.during the following year so it was never a company that acted in isolation

The Department of Health and Human Services disagreed with that reading of the statute and said so in an advisory opinion. Litigation in multiple federal courts followed and the results did not clearly agree. Different courts reached different conclusions about how much latitude the statute actually gives manufacturers to restrict shipments from contract pharmacies and years later there is still no single national rule resolving the issue. Several states responded with their own laws requiring manufacturers doing business within their borders to comply with thecontracted pharmacy agreements adding a layer of conflict between state mandates and the interpretation of federal laws

What I gather from this case study is not that either side was acting in bad faith. They both read an ambiguous decades-old statute and came to different conclusions about what it actually requires and the courts split the same way manufacturers and hospitals did. That's what happens when the most important expansion of a program contract pharmacy was never written into the original law in explicit terms. It grew through guidance and interpretation which means it can also be challenged.through guidance and interpretation

The Rebate Model Fight

The contract pharmacy litigation did not end the dispute. It merely moved it. Several manufacturers have proposed replacing the upfront discount with a rebate model. Under that structure the covered entity would pay full price at the time of purchase and then claim the 340B discount as a rebate supported by documentation showing that the prescription actually qualifies

Hospitals object for reasons beyond simple preference. Paying full price up front and expecting a refund means carrying the working capital cost of that gap for weeks or months and that's a real expense for an institution already operating on slim margins. Hospitals also argue that a rebate structure gives the manufacturer a practical mechanism to reject or delay claims after the fact in a way that an upfront discount would never allow since money already paid is much harder to recover than rejecting a refund request. This fightbetween refunds and initial discounts is the current front line of a broader dispute and is where I would first look for the next big thing in this area

What It Means for Reading Either Sector

For pharmaceutical manufacturers 340B has become an important and growing part of gross-to-net value the gap between a drug's list price and what the manufacturer actually gets after each discount rebate and chargeback. I would track it as its own line as a portion of revenue rather than letting it disappear into the standard gross-to-net trail

For hospital systems the $340 billion margin can represent a significant portion of operating revenue especially for systems that rely on high-infusion specialties like oncology. That's exactly why any adverse court ruling or regulatory change affecting the contract pharmacy or reimbursement model is a direct profit risk not an abstract political story. If you're reading presentations in either sector the most helpful you'll find is the specific disclosure that quantifies the program's impact. Oftenit is large and rarely presented front and center in the way its size would justify

How I'd Actually Read a 340B Disclosure

My first honest reaction to this program was that it sounded like a simple loophole and I think that reaction was wrong. The more time I spend on it the more it seems like a genuinely difficult trade-off between two things that are true at the same time: Hospitals need the subsidy and the subsidy has grown in ways that no one really designed on purpose

The way I would actually use this if I were looking at a hospital system or a pharmaceutical manufacturer is to treat 340B exposure as its own distinct line item rather than including it in reimbursement or raw or net as background noise. For a hospital system I would like to know what proportion of operating income the 340B differential represents and how concentrated that exposure is in a small number of high-cost infused drugs because concentration is exactly what makes a reimbursement model change or decisionof contract pharmacy is dangerous.For a manufacturer I would like to know if the 340 billion volume is growing faster than the rest of the book since that tells me if the mandatory discount is becoming a bigger drag on the realized price over time

I would also look at the legal calendar the same way I look at an earnings calendar. The fight over the reimbursement model and the litigation over contract pharmacies is unresolved and a hospital moving for or against it is a real catalyst not political background noise. This is one of the few cases where I think the legal history and the investment history are close to the same story closer than in most of the sectors I analyze. None of this is a reason to buy or sell anything foralone.It's a reason to know where the exposure is before an earnings call turns it into a surprise

The Bottom Line

The 340B program subsidizes safety-net providers by forcing a private industry to sell at a discount and then allowing the recipient to bill at full price with no obligation on what's left over. Both sides of this argument contain real truth at the same time. Hospitals really need a cross-subsidy that no other mechanism currently provides and the program actually operates far beyond the footprint for which it was designed expanded by an expansion of contract pharmacies that decoupled the site discount from the network ofsafety itself. The unresolved question was never whether safety net care deserves funding. It is whether an unsupervised spread in drug purchases whatever size market sets list prices and negotiated rates is a sensible mechanism for financing it or simply the mechanism that history left behind